ARTICLES
Prognostic factors for breast cancer: have they met their promise?
CK Osborne
JCO May 1 1992: 679–682. [PDF]
Search for the optimal treatment of ovarian cancer: heavy metals, "belly baths," and ... yew trees
F Muggia
JCO May 1 1992: 683–685. [PDF]
	Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
	G Gasparini, WJ Gullick, P Bevilacqua, JR Sainsbury, S Meli, P Boracchi, A Testolin, G La Malfa, and F Pozza
	JCO May 1 1992: 686–695. [Abstract] [PDF]
	Factors predicting treatment responsiveness and prognosis in node- negative breast cancer. The International (Ludwig) Breast Cancer Study Group
	AM Neville, R Bettelheim, RD Gelber, J Save-Soderbergh, BW Davis, R Reed, J Torhorst, R Golouh, HF Peterson, and KN Price
	JCO May 1 1992: 696–705. [Abstract] [PDF]
	Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer [published erratum appears in J Clin Oncol 1992 Sep;10(9):1505]
	DS Alberts, S Green, EV Hannigan, R O'Toole, D Stock-Novack, P Anderson, EA Surwit, VK Malvlya, WA Nahhas, and CJ Jolles
	JCO May 1 1992: 706–717. [Abstract] [PDF]
	Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group
	K Swenerton, J Jeffrey, G Stuart, M Roy, G Krepart, J Carmichael, P Drouin, R Stanimir, G O'Connell, and G MacLean
	JCO May 1 1992: 718–726. [Abstract] [PDF]
	Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer
	ML Rothenberg, RF Ozols, E Glatstein, SM Steinberg, E Reed, and RC Young
	JCO May 1 1992: 727–734. [Abstract] [PDF]
	Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells
	JW Greiner, F Guadagni, D Goldstein, RV Smalley, EC Borden, JF Simpson, A Molinolo, and J Schlom
	JCO May 1 1992: 735–746. [Abstract] [PDF]
	Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer
	N Kemeny, JA Conti, K Seiter, D Niedzwiecki, J Botet, D Martin, P Costa, J Wiseberg, and W McCulloch
	JCO May 1 1992: 747–752. [Abstract] [PDF]
	Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study
	PF Geertsen, GG Hermann, H von der Maase, and K Steven
	JCO May 1 1992: 753–759. [Abstract] [PDF]
	No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study
	CR Nichols, BJ Roth, SD Williams, I Gill, FM Muggia, DM Stablein, RB Weiss, and LH Einhorn
	JCO May 1 1992: 760–765. [Abstract] [PDF]
	Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance
	VA Levin and MD Prados
	JCO May 1 1992: 766–771. [Abstract] [PDF]
	Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine
	HM Kantarjian, MJ Keating, EH Estey, S O'Brien, S Pierce, M Beran, C Koller, E Feldman, and M Talpaz
	JCO May 1 1992: 772–778. [Abstract] [PDF]
	Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits
	JE Wagner, M Zahurak, S Piantadosi, RB Geller, GB Vogelsang, JR Wingard, R Saral, C Griffin, N Shah, and BA Zehnbauer
	JCO May 1 1992: 779–789. [Abstract] [PDF]
	Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma
	JR Redman, F Cabanillas, WS Velasquez, P McLaughlin, FB Hagemeister, F Swan, Jr, MA Rodriguez, WK Plunkett, and MJ Keating
	JCO May 1 1992: 790–794. [Abstract] [PDF]
	Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity
	RW Gregg, JM Molepo, VJ Monpetit, NZ Mikael, D Redmond, M Gadia, and DJ Stewart
	JCO May 1 1992: 795–803. [Abstract] [PDF]
	Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy
	GT Budd, S Murthy, J Finke, J Sergi, V Gibson, S Medendorp, B Barna, J Boyett, and RM Bukowski
	JCO May 1 1992: 804–809. [Abstract] [PDF]
	The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia
	DP Waber, NJ Tarbell, CM Kahn, RD Gelber, and SE Sallan
	JCO May 1 1992: 810–817. [Abstract] [PDF]
	Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer
	U Gatzemeier, DK Hossfeld, R Neuhauss, M Reck, W Achterrath, and L Lenaz
	JCO May 1 1992: 818–823. [Abstract] [PDF]
	Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
	K Mattson, G Giaccone, A Kirkpatrick, D Evrard, L Tammilehto, FJ van Breukelen, HT Planteydt, and N van Zandwijk
	JCO May 1 1992: 824–828. [Abstract] [PDF]
	Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research
	GM Strauss, MP Langer, AD Elias, AT Skarin, and DJ Sugarbaker
	JCO May 1 1992: 829–838. [Abstract] [PDF]
	Retinoids in cancer therapy
	MA Smith, DR Parkinson, BD Cheson, and MA Friedman
	JCO May 1 1992: 839–864. [Abstract] [PDF]
Sequential methotrexate and fluorouracil in colon cancer
JR Bertino and JC Marsh
JCO May 1 1992: 865a. [PDF]
Two studies have evaluated regional perfusion
L Hafstrom
JCO May 1 1992: 865b–866. [PDF]
Osteosarcoma: more news on the good news despite crude tools
N Jaffe
JCO May 1 1992: 866a. [PDF]
Secondary acute lymphoblastic leukemia in childhood
CB Pratt and CH Pui
JCO May 1 1992: 866b. [PDF]
The purine analogs--a therapeutic beauty contest [corrected and republished editorial originally printed in J Clin Oncol 1992 Mar;10(3):352-5]
BD Cheson
JCO May 1 1992: 868–871. [PDF]

SPECIAL DEPARTMENTS
Errata
	The Second Medical Research Council Study of Prognostic Factors in Nonseminomatous Germ Cell Tumors
	G.M. Mead, S.P. Stenning, M.C. Parkinson, A. Horwich, S.D. Fossa, P.M. Wilkinson, S.B. Kaye, E.S. Newlands, and P.A. Cook for the Medical Research Council Testicular Tumour Working Party
	JCO May 1 1992: 867. [Abstract] [PDF]
	ICRF-187 Permits Longer Treatment With Doxorubicin in Women With Breast Cancer
	James L. Speyer, Michael D. Green, Anne Zeleniuch-Jacquotte, James C. Wernz, Mariano Rey, Joseph Sanger, Elissa Kramer, Victor Ferrans, Howard Hochster, Marleen Meyers, Ronald H. Blum, Frederick Feit, Michael Attubato, Whitney Burrows, and Franco M. Muggia
	JCO May 1 1992: 867-a. [Abstract] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.